Mode
Text Size
Log in / Sign up
Phase 4 Completed N=96 Randomized Single-blind Treatment

12 Versus 20 mL PCB for D&E Cervical Prep

Source: ClinicalTrials.gov NCT03356145 ↗
Enrolled (actual)
96
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcomePrimary: Pain Immediately Following Dilator Insertion — 41; 49 score on a scale
◆ Published Evidence
Emerging
2citations · ~0 / year
A Comparison of Paracervical Block Volumes Before Osmotic Dilator Placement: A Randomized Controlled Trial.
Obstetrics and gynecology · 2021 · Likely link

Summary

More research is needed to investigate methods of pain control for cervical preparation for abortion procedures. Women report pain with paracervical block injection as well as with osmotic dilator placement. This study seeks to compare a 12 mL, 2-site 1% plain lidocaine paracervical block for pain control during cervical preparation (osmotic dilator insertion) for Dilation and Evacuation (D&E) to a 20 mL 1% lidocaine 2-site paracervical block.

Linked Publications

  • A Comparison of Paracervical Block Volumes Before Osmotic Dilator Placement: A Randomized Controlled Trial.
    Obstetrics and gynecology · 2021 · 2 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Immediately Following Dilator Insertion
41; 49
SECONDARY
Anticipated Pain Immediately Prior to Dilator Insertion
51; 58
SECONDARY
Patient Global Satisfaction Score
70; 53
SECONDARY
Total Procedure Time
5.5; 5.7
SECONDARY
Physician-reported Ease of Insertion
27; 17
SECONDARY
Count of Participants With Procedural Complications
0; 0
SECONDARY
Count of Participants With Side Effects Related to Lidocaine Administration
2; 3; 2; 3; 1; 6

Eligibility Criteria

Inclusion Criteria

  • Women 18 and older
  • Intrauterine pregnancy ≥16 weeks gestation
  • English speaking competency
  • Willing and able to sign consent forms
  • Agree to comply with study procedures

Exclusion Criteria

  • Women less than 18 years of age
  • IV conscious sedation
  • Known allergy to study medication (lidocaine)
  • Any women not meeting inclusion criteria above will be excluded from participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03356145) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search